Scorr-Insert
X

Find Psychiatry/Psychology Drugs in Phase II Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pimavanserin

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            Multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Palmidrol

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Evero

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 19, 2020

            Details:

            As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aloradine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            The proposed Phase 2A study of PH94B will an open-label basis and involve approximately 30 patients suffering from adjustment disorder with anxiety from stressors related to the pandemic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cytisinicline

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Company submitted required non-clinical supportive data for longer cytisinicline treatment to the U.S. Food & Drug Administration (FDA) in preparation for Phase 3 cytisinicline ORCA-2 trial initiation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lysergide

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Maastricht University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 12, 2020

            Details:

            As part of the agreement, Maastricht University will provide facilities and personnel for the Phase 2a Proof of Concept Clinical Trial for MindMed's multicentre trial evaluating the safety and efficacy of low dose LSD as treatment for ADHD in adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ebselen

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 04, 2020

            Details:

            The study shows important preliminary evidence of therapeutic activity for SPI-1005 in bipolar disorder. SPI-1005 treated patients had a 11.8-point reduction in Young Mania Rating Scale scores.

            Praxis Pharmaceutical

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRAX-114

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Blackstone Life Sciences

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Financing May 04, 2020

            Details:

            Praxis is deploying a precision medicine approach to develop high-impact therapies that target the underlying mechanisms of both prevalent and rare brain disorders with overlapping disease biology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATAI Life Sciences

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 27, 2020

            Details:

            The raised capital will help advancing the world's first large-scale psilocybin therapy clinical trial, performed by COMPASS, in 20 sites across nine countries in Europe and North America.

            Liechti Laboratory

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lysergide

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 21, 2020

            Details:

            This is the latest discovery based on surprising experimental results from work and collaboration conducted at the Liechti Laboratory.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PDC-1421

            Therapeutic Area: Psychiatry/Psychology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            Details:

            PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD).

            PharmaCompass